Nvidia-backed Iambic Therapeutics files for IPO with AbbVie partnership

By Splitfeed EditorialLast updated Sep 26, 2026, 20:10 UTC

On September 22, 2026, Iambic Therapeutics, an AI drug discovery company backed by Nvidia and the Qatar Investment Authority, filed for a US IPO. The filing was accompanied by news that pharmaceutical giant AbbVie had signed a partnership with the company ahead of its public listing, a move that signals industry-level validation rather than just venture capital enthusiasm. The following day, Bloomberg reported that Firmus, a separate Nvidia-backed AI startup targeting the Australian market, is seeking a valuation of $10 billion before its own IPO. The two listings are unrelated in sector and geography but share the common thread of Nvidia's backing and a compressed timeline, both emerging within the same week.

The broader significance is that Nvidia's investment portfolio is beginning to generate public market events at scale, which tests whether the valuations built during the private funding boom can hold up under public scrutiny. Iambic represents the specific thesis that AI can compress drug development timelines meaningfully enough to justify premium valuations. AbbVie's involvement before the IPO is commercially important because it suggests at least one major pharmaceutical buyer sees enough near-term utility to commit before the company's finances are fully public. What remains genuinely in dispute is whether AI drug discovery platforms have produced, or can produce, clinical results that justify the capital being deployed into them, and whether a $10 billion target for Firmus reflects real fundamentals or the residual heat of an Nvidia-adjacency premium.

None of the three camps, Pro-AI, Anti-AI, or Middle Ground, have published specific reactions to these stories. Pro-AI commentators would typically frame the AbbVie partnership and the dual IPO filings as confirmation that AI's commercial impact is moving from research labs into public markets and pharma pipelines. Anti-AI voices would likely question whether the valuations are driven by genuine performance data or by association with Nvidia's brand, pointing to the long and uncertain path from AI-assisted drug discovery to approved treatments. Middle Ground observers would probably acknowledge the legitimacy of the AbbVie signal while urging attention to clinical trial outcomes as the real measure of whether the underlying technology delivers.

The clearest near-term markers to watch are the Iambic IPO prospectus disclosures, which will show revenue figures and the financial terms of the AbbVie deal, and any pricing announcement from Firmus that either confirms or retreats from the $10 billion target. Clinical data from Iambic's pipeline, whenever it surfaces, will ultimately carry more weight than either listing price in settling the debate over whether AI drug discovery is delivering on its core promise.